Bioxodes, an innovative biotech company member of BioPark Charleroi, has reported positive Phase 2a clinical results for its innovative therapeutic candidate BIOX-101, developed for the treatment of intracerebral hemorrhage stroke. This important milestone underlines the excellence of Bioxodes. Congratulations to Marc Dechamps and his team.
To learn more about Bioxodes and this new milestone, read the full press release here.
MEMBERS & PARTNERS RELATED
Your Dynamic Snippet will be displayed here... This message is displayed because you did not provide both a filter and a template to use.